COVINGTON, Ky., March 5, 2019 /PRNewswire/ -- Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and other solid tumor patients enrolled with additional patients in screening. The purpose of Part 3 is to explore safety, and additional indications in rare and gastrointestinal tumors.
The Phase I Part 1 study showed that BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. Part 2 tested the highest dose in an additional 36 solid tumor patients. Preliminary data support a safe and tolerable drug profile.
"The safety profile of our drug illustrated in Phase I Part 1 and 2 of our trial has created enthusiasm about BXQ-350 among our Principal Investigators (PIs)," stated Dr. Ray Takigiku, Founder and CEO of Bexion. "The objective of Part 3 is to build and expand on the impressive results observed in our prior Phase 1 studies. The rapid enrollment is a reflection of the strong safety profile demonstrated for BXQ-350 and underscores the unmet medical need for new and novel treatment options in these patient populations."
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases. Bexion has completed multi-site first-in-human Phase 1 Parts 1 and 2 clinical studies of BXQ-350 for solid tumors and gliomas. A Phase 1 Part 3 expansion phase study is currently enrolling patients.
For more information, visit www.bexionpharma.com.
Media Contact: Margaret van Gilse ● 859.757.1652 ● email@example.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion's need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
SOURCE Bexion Pharmaceuticals, Inc.